Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 5/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6499707 | 0.80 | GAA (0.52) | GAATDP1L3MBTL1 | |
| SCHEMBL6489167 | 0.79 | GLA (0.54) | GAAL3MBTL1 | |
| SCHEMBL6498462 | 0.79 | GAA (0.51) | GAATDP1L3MBTL1TRPV1 | |
| SCHEMBL6500635 | 0.78 | EP300 (0.57) | GAAL3MBTL1 | |
| SCHEMBL5767044 | 0.76 | NPC1 (0.50) | KDR | |
| SCHEMBL24166697 | 0.75 | KDR (0.70) | KDR | |
| SCHEMBL7446132 | 0.74 | GAA (0.59) | GAATDP1L3MBTL1TRPV1 | |
| SCHEMBL27459501 | 0.72 | MEN1 (0.45) | GAATDP1L3MBTL1 | |
| SCHEMBL5146626 | 0.71 | GSK3B (0.49) | KDRGAA | |
| Water SCHEMBL5769374 | 0.71 | MEN1 (0.44) | GAATDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6908932-B2 | Cancer therapy | ICONIX PHARMACEUTICALS, INC. (US) | 2005-06-21 | — | — | US | disclosed |
| US-20030149074-A1 | Modulators of phosphoinositide 3-kinase | ENTELOS HOLDING CORP. | 2003-08-07 | — | — | US | disclosed |
| WO-2003035618-A2 | MODULATORS OF PHOSPHOINOSITIDE 3-KINASE | ICONIX PHARMACEUTICALS, INC. (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149074-A1 | Modulators of phosphoinositide 3-kinase | PIK3R1, PIK3R3, PIK3R4 | KDR 848/4885GAA 3724/4885TDP1 2263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.